Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
01. August 2024 09:00 ET
|
PRISM Mediawire
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
ONCOTELIC PRESENTING AT BIOPHARMA NEXUS CONFERENCE SAN DIEGO 2024
08. Mai 2024 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Biopharma Nexus Conference. Dr. Andy Hu, Nanomedicine Manager,...
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
05. Januar 2024 16:01 ET
|
Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
First Light Acquisition Group, Inc. Announces Effectiveness of Registration Statement and Sets August 22, 2023 as Date of Stockholder Meeting for the Calidi Business Combination
07. August 2023 05:00 ET
|
First Light Acquisition Group
RESTON, Va., Aug. 07, 2023 (GLOBE NEWSWIRE) -- First Light Acquisition Group, Inc. (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company, today announced that the U.S. Securities and...
KAIST and Checkmate Capital Complete Investment in Bredis Healthcare
25. Mai 2023 18:00 ET
|
Checkmate Capital
Investment Accelerates Bredis’ Capacity Expansion, Integrated Platform Development and Commercialization in Korea Further Announcement of Bredis’ Agreements with Major University Hospitals SEOUL,...
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
08. Dezember 2022 16:10 ET
|
Inotiv, Inc.
WEST LAFAYETTE, Ind., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and...
Endure Biotherapeutics, Inc. Announces Publication of Founder’s Seminal Work Regarding Colonizing Biotherapeutics
15. August 2022 23:41 ET
|
Endure Biotherapeutics, Inc.
San Diego, Aug. 15, 2022 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Endure Biotherapeutics, Inc. Announces Publication of Founder’s Seminal Work Regarding Colonizing Biotherapeutics Zarrinpar...
NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date
07. April 2022 11:00 ET
|
NeuroSigma, Inc.
Double-blind randomized controlled trial of eTNS for pediatric ADHD will enroll up to 150 participants at two sites in London and Southampton NeuroSigma’s Monarch eTNS System and electric patches to...
Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
11. Januar 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...
Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
05. Januar 2022 06:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today...